Genetics establishes inherited possibility
A pathogenic variant can meaningfully change risk management, but it does not by itself establish current disease.
Who it’s for · Known inherited risk
Genetics can show possibility. It cannot show what is happening today.
A known pathogenic variant can change a person’s surveillance plan for life. A current microRNA profile asks a separate question about active molecular patterns,adding context while leaving hereditary-risk care fully in place.
This page does not provide genetic or medical advice. People with known inherited risk should follow the surveillance plan established with their genetics and medical teams.
Known factorA confirmed inherited risk variant
Primary pathwayGenetic counselling and syndrome-specific surveillance
Different questionCurrent molecular pattern in today’s sample
Essential boundaryNever replace prescribed screening
Static risk and dynamic biology
The information layers are different,and that is why they can be complementary.
Genetic testing and microRNA analysis should not be collapsed into one claim. Each provides a different type of information.
Clinical programs remain the foundation
Syndrome-specific screening and preventive options are based on evidence and should continue exactly as advised.
microRNA may add another observation
A disease-associated pattern in the current sample may support a physician conversation, but it is not a diagnosis.
How it fits safely
Add context between surveillance events without creating false reassurance.
The added value only exists when the inherited-risk plan remains primary and both positive and negative results are interpreted carefully.
Keep the genetics team informed
Discuss additional testing within the care plan already established for the inherited condition.
Maintain every surveillance interval
Do not postpone colonoscopy, imaging, examination or other recommended procedures.
Use physician-reviewed results
A suspected signal requires follow-up; a result without a signal cannot eliminate inherited risk.
Study change over time responsibly
Longitudinal research may be valuable in defined high-risk cohorts when consent, endpoints and governance are explicit.
What this relationship creates
A highly defined need,and a demanding standard for clinical usefulness.
Known-risk populations make the value proposition clear: added information must improve context without disrupting proven surveillance.
Current context around lifelong risk
The person can distinguish inherited predisposition from a present-state molecular observation.
A defined place in an existing pathway
The result can be assessed against a documented syndrome, surveillance history and current clinical plan.
A well-characterized cohort
With consent and appropriate study design, inherited-risk cohorts may help test longitudinal hypotheses more rigorously.
Non-negotiable boundaries
An added test must never weaken proven surveillance.
Known inherited risk requires individualized medical care. General website information cannot substitute for that plan.
Maintain
The existing medical pathway
- Continue genetics follow-up and syndrome-specific surveillance.
- Follow the exact intervals recommended by your clinicians.
- Share additional test results with the appropriate care team.
- Seek direct evaluation for any new symptom.
Do not assume
The current test answers everything
- It does not identify or characterize inherited variants.
- It does not detect every cancer or every disease stage.
- A negative result does not reduce the inherited mutation itself.
- A suspected signal still requires diagnostic workup.
Keep every layer in its proper role
Inherited risk defines vigilance. Current information may add context.
Review the complete miCheckup intended use and discuss any additional testing with the team managing your hereditary risk.